homocastasterone: putative ecdysteroid antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5487654 |
| CHEMBL ID | 488432 |
| SCHEMBL ID | 20561406 |
| MeSH ID | M0191211 |
| Synonym |
|---|
| homocastasterone |
| stigmastan-6-one, 2,3,22,23-tetrahydroxy-, (2.beta.,3.alpha.,5.alpha.,22r,23r)- |
| (2r,3s,5s,8s,9s,10r,13s,14s,17r)-17-[(1s,2r,3r,4s)-4-ethyl-2,3-dihydroxy-1,5-dimethyl-hexyl]-2,3-dihydroxy-10,13-dimethyl-1,2,3,4,5,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-6-one |
| BA793800-32F2-4D3D-A855-8E2AE466F94F |
| 28-homocastasterone |
| CHEMBL488432 |
| (2r,3s,5s,8s,9s,10r,13s,14s,17r)-17-[(2s,3r,4r,5s)-5-ethyl-3,4-dihydroxy-6-methylheptan-2-yl]-2,3-dihydroxy-10,13-dimethyl-1,2,3,4,5,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-6-one |
| 28-homo castasterone |
| 2,3,22,23-tetrahydroxystigmastan-6-one |
| 2,3,22,23-tetrahydroxy-5alpha-stigmastan-6-one |
| 83509-42-6 |
| stigmastan-6-one, 2,3,22,23-tetrahydroxy-, (2alpha,3alpha,5alpha,22r,23r)- |
| SCHEMBL20561406 |
| (22r,23r,24s)-2a,3a,22,23-tetrahydroxy-24-ethyl-5a-cholestan-6-one |
| DTXSID101003492 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " For every pair of structurally related compounds, (22R,23R) isomer was found to be significantly more toxic than (22S,23S) isomer." | ( Toxicity of (22R,23R)-22,23-dihydroxystigmastane derivatives to cultured cancer cells. Khripach, VA; Mehtiev, AR; Misharin, AY; Timofeev, VP; Tkachev, YV; Zhabinskii, VN, 2010) | 0.36 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID431876 | Cytotoxicity against human BJ cells after 72 hrs by calcein-AM assay | 2009 | Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18 | Synthesis of fluorinated brassinosteroids based on alkene cross-metathesis and preliminary biological assessment. |
| AID344325 | Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by calcein-AM assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Brassinosteroids: synthesis and activity of some fluoro analogues. |
| AID344326 | Cytotoxicity against human RPMI 8226 cells assessed as cell survival after 72 hrs by calcein-AM assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Brassinosteroids: synthesis and activity of some fluoro analogues. |
| AID431874 | Cytotoxicity against human CEM cells after 72 hrs by calcein-AM assay | 2009 | Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18 | Synthesis of fluorinated brassinosteroids based on alkene cross-metathesis and preliminary biological assessment. |
| AID431875 | Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay | 2009 | Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18 | Synthesis of fluorinated brassinosteroids based on alkene cross-metathesis and preliminary biological assessment. |
| AID344327 | Cytotoxicity against human BJ cells assessed as cell survival after 72 hrs by calcein-AM assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Brassinosteroids: synthesis and activity of some fluoro analogues. |
| AID344324 | Cytotoxicity against human CEM cells assessed as cell survival after 72 hrs by calcein-AM assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Brassinosteroids: synthesis and activity of some fluoro analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||